1. Systemic Sclerosis With Interstitial Lung Disease

2. Overview

3. Major Subsets of SSc

4. Overview of Major SSc Complications

5. Survival in SSc Is Determined by Subset and Organ-Based Manifestations

6. Differences Between Diffuse and Limited SSc: Cumulative Frequency of Major Organ-Based Complications

7. Pathogenesis of SSc

8. Cellular Pathogenesis of Fibrotic Lung Injury

9. Microarray Analysis of SSc Lung Tissue

10. Genes With > 10-Fold Overexpression in SSc-ILD vs Control

11. Esophageal Dilation and ILD in SSc

12. Impact of Pulmonary Complications on Survival in SSc

13. Patterns of ANA Reactivity in SSc

14. Autoantibody Reactivity Predicts Outcomes in SSc

15. Multiple Mechanisms for Dyspnea in SSc

16. Histological Classification of IIPs in CTD

17. HRCT Assessment in SSc

18. HRCT Scoring System: Quantification of Extent of ILD

19. Histological Classification of SSc-ILD

20. Impact of Histological Subtype on Outcome in SSc-ILD

21. A Simple Staging System for Treatment Decisions in SSc-ILD

22. Disease Extent: Impact on Survival

23. Epithelial Injury As a Marker of Progression in SSc-ILD: Serum KL-6

24. Short-Term Pulmonary Function Trends Predict Mortality in SSc-ILD

25. Decline in DLco and Kco Predicts Outcome at 24 Months

26. Association of Severe Lung Fibrosis in SSc

27. Management of Lung Fibrosis in SSc: Royal Free Hospital Protocol

28. Oral Cyclophosphamide in SSc-PF: The SLS I Study

29. SLS II Outcome Data: Frequency Distribution of Changes from Baseline to 24 Months in % Predicted

30. Targeted Therapy in SSc

31. Conclusions

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)